Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE Small Cap

597.00p
   
  • Change Today:
    -5.00p
  • 52 Week High: 605.00p
  • 52 Week Low: 232.50p
  • Currency: UK Pounds
  • Shares Issued: 120.18m
  • Volume: 74,423
  • Market Cap: £717.49m
  • RiskGrade: 125

OXB Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -30.6% -13.9%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 5.6 4.5
Pr/Book 12.0  
Latest F'cast
Revenue 43.8% 25.8%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

OXB Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 87.73 (6.57) (7.81)p n/a n/a n/a n/a 0.0%
31-Dec-21 142.80 19.88 22.77p 54.0 n/a n/a n/a 0.0%
31-Dec-22 139.99 (45.98) (41.29)p n/a n/a n/a n/a 0.0%
31-Dec-23 89.54 (188.53) (163.11)p n/a n/a n/a n/a 0.0%
31-Dec-24 128.80 (47.26) (41.75)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

OXB Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 162.04 (22.52) (28.87)p n/a n/a n/a n/a 0.0%
31-Dec-26 212.91 2.18 (10.84)p n/a n/a n/a n/a 0.0%
31-Dec-27 254.93 24.06 5.37p 112.1 n/a n/a n/a 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

OXB Company Announcements

Total Voting Rights 01-Sep-2025 07:00 RNS
PDMR Dealings 22-Aug-2025 15:36 RNS
Holding(s) in Company 21-Aug-2025 10:24 RNS

OXB ShareCast News

RBC Capital Markets raises target price on OXB 26-Aug-2025 ShareCast
Oxford Biomedica raises £60m to bolster US capac... 15-Aug-2025 ShareCast
Oxford Biomedica agrees new four-year, $125m loa... 01-Aug-2025 ShareCast

OXB Top Newspaper Links

Need to know: Opec cuts forecast ... Tesco cuts ... 16-Aug-2008 Times
Need to know 10-May-2008 Times
DSG International may be losing its spark 12-Feb-2008 Telegraph

Latest OXB Director Deals

Traded Action Notifier PriceAmountValue
18-Aug-25 Sell Dame Kay Davies 500.40p 4,563 £22,833.25
15-Aug-25 Buy Roch Doliveux 449.75p 67,000 £301,332.50
11-Aug-25 Buy Dame Kay Davies 436.00p 4,563 £19,894.68

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

OXB Market Data

Currency UK Pounds
Share Price 597.00p
Change Today -5.00p
% Change -0.83 %
52 Week High 605.00p
52 Week Low 232.50p
Volume 74,423
Shares Issued 120.18m
Market Cap £717.49m
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
35.16% below the market average35.16% below the market average35.16% below the market average35.16% below the market average35.16% below the market average
17.07% above the sector average17.07% above the sector average17.07% above the sector average17.07% above the sector average17.07% above the sector average
Price Trend
84.11% above the market average84.11% above the market average84.11% above the market average84.11% above the market average84.11% above the market average
86.36% above the sector average86.36% above the sector average86.36% above the sector average86.36% above the sector average86.36% above the sector average
Income Not Available
Growth
5.07% above the market average5.07% above the market average5.07% above the market average5.07% above the market average5.07% above the market average
24.14% below the sector average24.14% below the sector average24.14% below the sector average24.14% below the sector average24.14% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 0
Strong Sell 0
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 11-Sep-2025

Time Volume / Share Price
13:35 80 @ 597.00p
13:35 161 @ 597.00p
13:35 531 @ 597.00p
13:35 2,100 @ 597.00p
13:35 317 @ 597.00p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page